Tesofensine (NS2330) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that is being developed for the treatment of obesity. It was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.
Tesofensine acts by blocking the reuptake of serotonin, norepinephrine, and dopamine in the brain. This increases the levels of these neurotransmitters in the brain, which can lead to a number of effects, including:
- Reduced appetite
- Increased feelings of fullness
- Increased energy expenditure
- Improved mood
Tesofensine has been shown to be effective in reducing body weight and body fat in clinical trials. In one study, participants who took tesofensine for 24 weeks lost an average of 12.6% of their body weight, compared to 6.5% in participants who took a placebo.
Tesofensine is also well-tolerated in most people. The most common side effects are mild and go away on their own, such as dry mouth, nausea, and insomnia.
Tesofensine is not currently approved for any use by the US Food and Drug Administration (FDA). However, it is in Phase III clinical trials for the treatment of obesity, and it is expected to be submitted for FDA approval in 2023.
In addition to its potential for the treatment of obesity, tesofensine is also being investigated for the treatment of other conditions, such as:
- Parkinson’s disease
- Alzheimer’s disease
- Attention deficit hyperactivity disorder (ADHD)
- Depression
However, more research is needed to confirm the safety and efficacy of tesofensine for these conditions.
Overall, tesofensine is a promising new drug for the treatment of obesity. It has been shown to be effective in reducing body weight and body fat, and it is well-tolerated in most people. Tesofensine is currently in Phase III clinical trials for the treatment of obesity, and it is expected to be submitted for FDA approval in 2023.
Here is a summary of the key points about tesofensine:
- Tesofensine is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that is being developed for the treatment of obesity.
- Tesofensine works by increasing the levels of serotonin, norepinephrine, and dopamine in the brain.
- Tesofensine has been shown to be effective in reducing body weight and body fat in clinical trials.
- Tesofensine is well-tolerated in most people. The most common side effects are mild and go away on their own.
- Tesofensine is not currently approved for any use by the US Food and Drug Administration (FDA). However, it is in Phase III clinical trials for the treatment of obesity, and it is expected to be submitted for FDA approval in 2023.
- Tesofensine is also being investigated for the treatment of other conditions, such as Parkinson’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD), and depression. However, more research is needed to confirm the safety and efficacy of tesofensine for these conditions.
